long intergenic non-protein coding RNA 2461Genealiases: []
Q-omics provides the consensus-scored LINC02461 profile across patient tissues and cancer cell-line models. LINC02461 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, LINC02461 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, LINC02461 RNA expression shows 12,677 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight OV, THCA, and PDAC as cancer lineages where LINC02461 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02461 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02461 survival associations across molecular data types. LINC02461 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02461 RNA expression–survival associations across cancer types. High LINC02461 expression shows unfavorable associations in OV, UVM, ACC, KIRC and KIRP, but favorable associations in BRCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for LINC02461 RNA expression.
This table summarizes LINC02461 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02461. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02461 shows lower tumor expression in KICH and BLCA and higher tumor expression in THCA, HNSC, BRCA and STAD. The THCA box plot shows higher LINC02461 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with LINC02461 in patient tissues and cancer cell lines. In patient samples, LINC02461 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
